Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
In this week’s Pathways Picks: FDA details expectations for surgical robots and plans for the future; Anthropic, OpenAI add heft to AI cardiologist initiative; Google recruits; FDA seeks more advisory panelists; World Health Organization expands device focus; Singapore introduces premarket checklist; Medicare considers hepatitis C screening coverage; and more global updates.
Coronary microvascular disease can contribute to major cardiovascular pathology, but there are no approved disease-modifying therapies. On the hunt for a new solution, VahatiCor is pursuing a new device that narrows coronary sinus flow to improve perfusion in the microvascular network.
MDFS announces its variation on staged approvals for AI. Excerpted from Pathways Picks September 16: TAVR Coverage, New AI Routes, Harmonization Actions, and More.